CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 1,410 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Dexmedetomidine 0.2 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04204798
NCT04204798N/AActive

Impact of Low-dose Dexmedetomidine on Outcomes of Elderly Admitted to ICU After Noncardiac Surgery: a Randomized Controlled Trial

Peking University First Hospital·interventional·Posted Dec 19, 2019·Updated Jul 31, 2025

In Brief

A clinical study evaluating Dexmedetomidine and Placebo for Elderly and 4 related conditions. Active but no longer recruiting, targeting 1,410 participants across 1 site.

Detailed Summary

Sleep disorder and delirium are common problems in intensive care unit (ICU) patients, and may lead to poor prognosis. The investigators' previous study showed that nighttime infusion of low-dose dexmedetomidine improved the sleep quality and decreased the incidence of delirium in ICU patients after surgery. Long-term follow-up of these patients showed that low-dose dexmedetomidine also improved 2-year survival and the quality of life in 3-year survivors. The purpose of this study is to investigate the effect of low-dose dexmedetomidine on the long-term outcome of elderly patients admitted to the ICU after noncardiac surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina

Timeline

N/AActiveOverdue
2020202120222023202420252026
First PostedDec 19, 2019
Enrollment StartAug 28, 2020
Primary CompletionJun 4, 2025
Study CompletionJun 4, 2026
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 6.5 years ago

Interventions

Dexmedetomidinedrug

1. Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days. 2. For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events. 3. For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events.

Placebodrug

1. Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group. 2. Propofol sedation is administered when considered necessary.